Centene Corporation filings document operating and financial disclosures for a government-focused managed care company. Form 8-K reports furnish quarterly results press releases, GAAP and adjusted EPS guidance, non-GAAP financial measure disclosures, conference-related Regulation FD updates and material-event reports tied to company performance.
Centene's proxy and governance filings cover annual meeting matters, board and executive compensation disclosures, equity awards, officer appointments and related corporate governance topics. Other filings address material agreements, forward-looking-statement disclosures and formal exhibits filed or furnished with the SEC.
Centene Corporation reported an equity grant to Corporate Controller & CAO Katie Casso. On January 26, 2026, she was awarded 26,036 shares of common stock at a price of $0, reflecting compensation rather than an open-market purchase.
The grant consists of 13,018 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 13,018 performance stock units that may vest on March 15, 2029, from 0% to 200% of target based on Centene’s stock price performance between late 2025 and late 2028. After this award, Casso beneficially owns 122,371 shares, including 62,561 previously granted restricted and performance stock units that remain subject to vesting.
Centene Corporation’s Chief Financial Officer, Asher Andrew Lynn, reported an equity award of 173,573 shares of common stock on January 26, 2026, at a price of $0 per share. This grant brings his directly held beneficial ownership of Centene common stock to 831,215.48 shares.
The award includes 69,429 restricted stock units that vest in three annual installments beginning March 15, 2027, and 104,144 performance stock units reported at target, which may vest on March 15, 2029 from 0% to 200% of target based on stock price performance tests. He also holds 13,449 performance stock options with a $81.85 exercise price expiring December 15, 2031, which become exercisable only if Centene’s stock trades at or above $100 for 20 consecutive trading days after the December 15, 2021 grant date.
Centene Corp’s Chief People Officer, Tanya M. McNally, reported a routine tax-related share transaction. On 01/15/2026, 725 shares of Centene common stock were withheld at a price of $46.17 per share to cover taxes due on the vesting of a previously reported grant of restricted stock units. After this withholding, she beneficially owns 58,769 shares of Centene common stock, which includes 49,340 shares in the form of previously granted restricted stock units and performance stock units reported at target performance and still subject to vesting requirements.
Centene Corporation director reports a routine stock grant. On 12/31/2025, the reporting person acquired 790 shares of Centene common stock at a price of $0, indicating an award rather than an open-market purchase.
After this grant, the director beneficially owned 6,738 shares of Centene common stock in direct ownership. The filing also explains that this total includes 3,579 shares of restricted stock units that are subject to vesting requirements, meaning some shares will only be fully owned if those conditions are met.
Centene Corp director updates equity ownership in a routine insider filing. On 12/31/2025, the director acquired 608 shares of Centene common stock at a reported price of $0, likely reflecting a grant rather than an open-market purchase. Following this transaction, the director beneficially owns 19,812.979 shares directly, including 3,579 restricted stock units that are subject to vesting requirements, and 32,000 shares held indirectly through a revocable family trust where he serves as co‑trustee.
The filing also lists a stock option giving the right to buy 10,000 shares of Centene common stock at an exercise price of $80.57, exercisable from 02/07/2025 until 02/07/2032, with all 10,000 derivative securities currently reported as beneficially owned.
Centene Corp director Christopher A. Koster reported acquiring 608 shares of Centene common stock on 12/31/2025 at a price of $0 per share. Following this transaction, he beneficially owned 360,360.658 shares of Centene common stock in total. The filing notes that this ownership includes 5,965 shares of restricted stock units that are subject to vesting requirements. The securities are held in direct ownership form.
Centene Corporation director Robert K. Coughlin reported updated holdings of the company’s stock and options. On 12/31/2025, he acquired 729 shares of common stock at a stated price of $0, bringing his directly held common stock to 13,016.926 shares.
He also reports 30,054 shares held indirectly through a grantor retained annuity trust. His ownership includes 3,579 restricted stock units that are subject to vesting. In addition, he holds a stock option to buy 10,000 Centene common shares at an exercise price of $80.57, exercisable from 02/07/2025 until expiration on 02/07/2032.
Centene Corporation director Robert K. Burdick reported a small increase in his ownership of company stock. On 12/31/2025, he acquired 729 shares of common stock at $0, which typically reflects a vested equity award rather than an open-market purchase. After this transaction, he directly holds 273,093.924 shares of Centene common stock.
Burdick also reports 86,498 shares held indirectly through Burdick Family LLC, where he is a chief manager and disclaims beneficial ownership except for his economic interest. His reported ownership includes 3,579 restricted stock units that are still subject to vesting. In addition, he holds a stock option to buy 10,000 shares at $80.57 per share, exercisable starting 02/07/2025 and expiring on 02/07/2032.
Centene Corp director reports stock sales and remaining holdings. A Centene Corp (CNC) director sold 33,211 shares of common stock on 12/03/2025 at a weighted average price of $39.04 per share, and 32,796 shares on 12/04/2025 at $39.00 per share. After these transactions, the director directly beneficially owned 305,160.924 shares of Centene common stock, which include 3,579 restricted stock units that are subject to vesting requirements. In addition, the director had indirect beneficial ownership of 86,498 shares held by Burdick Family LLC, for which he is a chief manager and disclaims beneficial ownership except for his pecuniary interest. The filing also notes stock options covering 10,000 shares of common stock at an exercise price of $80.57, exercisable from 02/07/2025 until 02/07/2032.
CNC shareholder Kenneth Burdick filed a Form 144 notice covering a planned sale of 32,796 shares of common stock through Fidelity Brokerage Services LLC on 12/04/2025 on the NYSE. The filing lists an aggregate market value of about $1,279,044.00 for these shares, compared with 491,518,000 shares of the same class reported as outstanding.
The shares to be sold were acquired through restricted stock vesting from the issuer as compensation, including 31,916 shares on 07/23/2021 and 880 shares on 02/06/2024, both fully paid as compensation on the respective vesting dates. The notice also discloses that Burdick sold 33,211 shares of common stock during the past three months, on 12/03/2025, for gross proceeds of $1,296,621.24. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.